The fully automated serology test for the detection of SARS-CoV-2 IgG Antibodies
Coronavirus disease (COVID-19) is a respiratory infectious disease caused by the newly discovered coronavirus SARS-CoV-2. The first cases were reported by Chinese authorities in December 2019, in Wuhan City, Hubei province. The initial outbreak in Wuhan spread rapidly, affecting first other regions of China and then an increasing number of countries world- wide. The Director General of the World Health Organization declared COVID-19 a global pandemic on 11 March 2020. (1) The first COVID-19 patient in Sri Lanka was identified early February 2020, and within two months the total number of confirmed cases in Sri Lanka has gone up to 700 and still counting.
Detection of COVID-19
There are two different methods that are being used to detect COVID-19.
- Molecular Diagnosis of COVID-19 using RT-PCR technology.
- Serological test to identify antibodies against SARS-CoV2 virus.
Serological Tests: Fast and Easy
When compared to a molecular diagnostic method, a serological test is always easy to perform as it can be done by using even a small blood sample. So these tests are most of the time referred as Rapid tests. In these tests we check the presence of antibodies in our blood against this COVID-19 causing virus.
LIAISON® SARS-CoV-2 S1/S2 IgG Test
The LIAISON® SARS-CoV-2 S1/S2 IgG uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of anti-S1 and anti-S2 specific IgG antibodies to SARS-CoV-2 in human serum or plasma samples. The assay is intended as an aid in the diagnosis of CoVID-19 and to support the study of the immune status of infected patient by providing an indication of presence of neutralizing IgG antibodies against SARS-CoV-2. However, the result of the test alone cannot be used to exclude that the patient is still infectious.
The new LIAISON® SARS-CoV-2 S1/S2 IgG test provides diagnostic laboratories with:
• A fully automated quantitative solution for the detection of IgG antibodies against S1/S2 antigens of SARS-CoV-2
• Up to 170 results/hour on LIAISON® XL
• Detection of Neutralizing antibodies: 94.4% positive agreement to Plaque Reduction Neutralization Test (PRNT)
• High sensitivity and specificity to assure accurate results
More information – Product Brochure